Soft Tissue Repair
De-risking scale-up, strengthening clinical and commercial value
Advancing Sustainable Innovation in FemTech
Client: Neotherix is a UK-based regenerative wound care innovator developing a scaffold technology designed to improve surgical repair outcomes in complex wounds, with a particular focus on women’s health.
Approach: Pd-m delivered a structured sustainability and manufacturing work programme. This included Neotherix’s first Carbon Reduction Plan, a cradle-to-grave product carbon footprint, and a targeted manufacturing optimisation study. The work examined materials, transport, assembly, sterilisation, end-of-life, and scale-up risks, alongside future data requirements for credible carbon accounting.
Challenges: As Neotherix prepared to enter clinical evaluation, they were responding to an SBRI FemTech funding call highlighting the historic underinvestment in female health. They needed robust evidence to underpin claims around sustainability, manufacturability, and healthcare value—while ensuring their growth strategy aligned with NHS Net Zero expectations.
Deliverables: Pd-m delivered Neotherix’s first NHS-ready Carbon Reduction Plan with a Net Zero scale-up roadmap, a cradle-to-grave product carbon footprint focused on manufacturing, and a manufacturing optimisation report highlighting ways to reduce waste, failures, and cost through automation, tooling, and protective packaging.
Impact: The project put data behind Neotherix’s assumptions, strengthening their clinical, environmental, and economic value proposition—the “triple bottom line”. It de-risked scale-up, supported funding and procurement conversations, and positioned sustainability as a core enabler of better patient outcomes and more efficient healthcare delivery.
“Pd-m brought the expertise we needed to quantify our scaffold’s carbon footprint, optimise manufacturing, and plan for Net Zero scale-up. Their structured approach provided data-backed insights, highlighted risks, and identified practical solutions to reduce waste, failures, and cost.
This work strengthened our value proposition for clinical evaluation, procurement, and funding discussions. Pd-m’s combination of medtech knowledge and sustainability experience made them uniquely suited to deliver this critical project.”